The global market for breast cancer screening tests, also called breast cancer assessment tests, is growing steadily. Valued at USD 4.44 billion in 2024, the market is expected to reach USD 8.77 billion by 2034, with a compound annual growth rate (CAGR) of 7.04%, according to a study by Towards Healthcare, a sister company of Precedence Research.
Key Market Highlights
- Market Size: USD 4.75 billion in 2025; projected to reach USD 8.77 billion by 2034.
- Growth Rate: 7.04% CAGR from 2025 to 2034.
- Leading Region: North America dominated the market in 2024.
- Fastest-Growing Region: Asia Pacific expected to show the fastest growth during 2025–2034.
- Top Test Type: Imaging tests led the market in 2024.
- Emerging Test Type: Blood marker tests are expected to grow rapidly.
- Sample Type Leaders: Tissue biopsy currently dominates; blood samples are the fastest-growing segment.
- Collection Sites: Hospitals lead, but home-based testing is expanding quickly.
- Applications: Early detection is the major application; post-treatment monitoring is rising.
- End Users: Healthcare providers hold the largest share; home users are the fastest-growing segment.
Breast Cancer Screening Tests: What They Are
Breast cancer assessment tests include mammography, ultrasound, and MRI. New technologies like 3D mammography (tomosynthesis) and AI-assisted analysis are improving detection accuracy. The growth of this market is driven by rising cancer cases, increased patient awareness, advances in screening technologies, and government initiatives.
The U.S. Preventive Services Task Force recommends annual mammograms for women starting at age 45 for average-risk individuals.
Market Drivers
- Awareness Campaigns: Governments and private organizations are emphasizing early detection to improve survival rates.
- Technological Advances: Companies are developing innovative diagnostic tools using biomarkers, such as ELISA and immunohistochemistry.
Market Trends
- October 2025: Color Health partnered with Google Cloud to speed up breast cancer screening access.
- September 2025: Breast Cancer Research Foundation invested $74.75 million in global breast cancer research.
- July 2025: Medtech startup Blue Box raised €3M to innovate screening solutions.
Market Challenges
High costs of 3D mammography, MRI, and AI-based tools remain a barrier. Implementing AI also requires data storage, system compatibility, and trained professionals.
Regional Insights
North America
Dominates due to rising breast cancer cases, fast adoption of new technology, and government support. In June 2025, the FDA approved Clairity Breast, the first AI platform to predict a woman’s five-year breast cancer risk.
Asia Pacific
Expected to grow fastest due to aging populations, increasing healthcare investment, and adoption of mobile health and AI technologies. In October 2025, Gene Solutions partnered with AMPATH to launch an advanced genomics lab in Hyderabad.
Segment Insights
By Test Type
- Imaging tests lead, driven by AI-enhanced mammography and contrast-enhanced spectral mammography.
- Blood marker tests, including liquid biopsies, are expected to expand rapidly.
By Sample Type
- Tissue biopsy dominates; blood-based testing is growing fastest.
- Blood tests now include AI-assisted analysis of circulating tumor DNA for early detection and monitoring.
By Collection Site
- Hospitals remain the main site for testing.
- Home-based testing is increasing with wearable devices and AI-driven home solutions.
By Application
- Early detection leads, improving survival and treatment options.
- Post-treatment monitoring is expanding with advanced imaging and ctDNA blood tests.
By End User
- Healthcare providers dominate due to demand for advanced diagnostics.
- Home users grow fastest with telehealth and wearable monitoring solutions, including MIT’s ultrasound bra patch.
Notable Developments in 2025
- Punjab: Introduced AI-assisted screening for breast and cervical cancer.
- Axia Women’s Health: Rolled out FDA-approved AI technology for affordable mammograms.
- SimonMed Imaging: Launched AI-powered Personalized Breast Cancer Detection program.
Related topics
Breast Cancer Assessment Test Doubles Detection in Dense Breasts
5 Common Myths About Side Effects of Hysterectomy Debunked
How Breast Self-Checks Protect Nursing Parents from Hidden Risk
